.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
Citi
Boehringer Ingelheim
Mallinckrodt
Daiichi Sankyo
Chinese Patent Office
Harvard Business School

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,245,819

« Back to Dashboard

Which drugs does patent 6,245,819 protect, and when does it expire?


Patent 6,245,819 protects OSPHENA and is included in one NDA.

This patent has thirty-eight patent family members in twenty-eight countries.

Summary for Patent: 6,245,819

Title: Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Abstract:This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.
Inventor(s): Halonen; Kaija (Rusko, FI), Kangas; Lauri (Raisio, FI), DeGregorio; Michael W. (Granite Bay, CA)
Assignee: Hormos Medical Oy, Ltd. (FI) Tess Diagnostics and Pharmaceuticals, Inc. (Granite Bay, CA)
Application Number:09/625,199
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,245,819

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,984,665Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women► Subscribe
9,566,252Method for the alleviation of dyspareunia in women► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,245,819

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1446085► Subscribe
China1287775► Subscribe
Czech Republic20030026► Subscribe
Czech Republic299439► Subscribe
Germany60112301► Subscribe
Denmark1305014► Subscribe
Estonia200300031► Subscribe
Estonia05344► Subscribe
Spain2241819► Subscribe
European Patent Office1305014► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Merck
AstraZeneca
Fuji
Accenture
Cipla
Mallinckrodt
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot